Related Experiment Video
Updated: Apr 4, 2026
08:17
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
11.7K
Roflumilast: A Review in COPD
1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
Drugs
|September 5, 2015
Summary
Roflumilast, a phosphodiesterase 4 inhibitor, effectively treats severe chronic obstructive pulmonary disease (COPD) by reducing inflammation and exacerbations. It offers improved lung function and is generally well-tolerated, making it a valuable COPD treatment option.
Area of Science:
- Pharmacology
- Pulmonology
- Clinical Medicine
Background:
- Selective phosphodiesterase 4 (PDE4) inhibition is a therapeutic strategy for chronic obstructive pulmonary disease (COPD).
- Roflumilast targets PDE4 to reduce systemic and pulmonary inflammation in COPD patients.
Purpose of the Study:
- To review the pharmacological profile of roflumilast.
- To evaluate the clinical efficacy and tolerability of roflumilast in moderate to severe COPD patients.
Main Methods:
- Literature review of pharmacological properties.
- Analysis of clinical trial data on efficacy and safety.
Main Results:
- Roflumilast improves lung function and reduces exacerbation risk in moderate to severe COPD.
- Common side effects include diarrhea; psychiatric events and weight loss are potential concerns.
- No increased risk of respiratory infection; potential cardiovascular benefits observed.
Conclusions:
- Roflumilast is an effective treatment for moderate to severe COPD, particularly for those with chronic bronchitis.
- It offers a favorable risk-benefit profile and is a valuable addition to COPD management strategies.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
01:24Chronic Obstructive Pulmonary Disease
3.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.2K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K
01:20COPD: Pathogenesis and Clinical Features
2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.3K